Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.
Cancer medicine(2023)
Abstract
Negative expression of CDX2 is an independent risk factor for survival in stage II/III GC, but subsequent adjuvant chemotherapy is able to compensate for this unfavorable effect. Therefore, active chemotherapy is more urgent for patients with negative CDX2 expression than for patients with positive CDX2 expression.
MoreTranslated text
Key words
adjuvant chemotherapy,CDX2,gastric cancer,immunohistochemistry,mucin
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined